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Scientific environment 
“The Intertan Study” (papers I and IV) was performed at the Orthopaedic Department, 
Haukeland University Hospital (HUS), and in close teamwork with the Clinical 
Research Unit and the Department of Radiology at HUS. “The Intertan Study” was 
also based on a close collaboration with 4 other Norwegian hospitals; Levanger 
Hospital, Akershus University Hospital, Diakonhjemmet Hospital, and Vestfold 
Hospital.  
Papers II and III were based on data from, and written together with colleagues from 
the Norwegian Hip Fracture Register (NHFR). This register is an integrated part of the 
Norwegian Arthroplasty Register (NAR) and the Orthopaedic Department, Haukeland 
University Hospital, Bergen 
Since 2009 I have been a PhD-candidate at the Department of Surgical Sciences, 
University of Bergen, Bergen, Norway.  
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1. List of abbreviations 
SHS  Sliding hip screw 
TSP  Trochanteric stabilizing plate 
IM nail  Intramedullary nail 
RCT    Randomized controlled trial 
AO/OTA   Arbeitsgemeinshaft für Osteosyntesefragen / Orthopaedic Trauma 
Association 
NHFR   Norwegian Hip Fracture Register 
NAR   Norwegian Arthroplasty Register 
TAD    Tip-apex distance 
TUG-test   Timed Up & Go-test 
VAS     Visual analogue scale 
HHS   Harris hip score 
EQ-5D EuroQuol-5Dimensions (quality of life measure) 
n  Numbers 
Et al.  And co-workers 
ASA-class American Association of Anaesthesiologists classification of co-
morbidities 
P-value Probability  
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3. Abstract 
%DFNJURXQG  
Trochanteric and subtrochanteric fractures are usually treated with a sliding hip screw 
(SHS) or an intramedullary (IM) nail, and the question whether a SHS or an IM nail 
should be the preferred implant for all or subgroups of fractures has not come to a final 
conclusion. In recent years, there has been a trend towards more use of IM nails, but 
this trend has not been driven by better results in well designed clinical trials. 
Regardless of type of implant, complications have to be encountered and to which 
extent modern implants have improved results remains unclear. 
$LPV  
It was our first aim to assess whether treatment with the new TRIGEN INTERTAN 
intramedullary nail resulted in less postoperative pain, better function, and improved 
quality of life for patients with trochanteric and subtrochanteric fractures compared to 
treatment with the SHS (3DSHUV,DQG,9). Surgical complications and reoperation 
rates were also assessed. 
Secondly, we wanted to compare postoperative pain, function, quality of life, and 
reoperation rates for patients operated with IM nails and SHS for different subgroups 
of trochanteric and subtrochanteric fractures at a national level 3DSHUV,,DQG,,,. 
3DWLHQWVDQGPHWKRGV
684 elderly patients with trochanteric and subtrochanteric fractures were included and 
treated with a SHS or the Intertan nail in a multicenter randomized controlled trial 
(RCT) 3DSHU,. The patients were assessed during hospital stay and at 3 and 12 
months postoperatively. The 159 patients with reverse oblique trochanteric (AO/OTA 
type A3)and subtrochanteric fractures were separately analyzed and discussed in 
depth 3DSHU ,9.  
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Using data from the Norwegian Hip Fracture Register in papers II and III, we analyzed 
7643 operations for simple two-part trochanteric fractures (AO/OTA type A1) 3DSHU
,, and 2716 operations for reverse oblique and subtrochanteric fractures 3DSHU,,, 
after treatment with either a SHS or an IM nail. 
5HVXOWV  
As presented in 3DSHUV,DQG,9 patients operated with the Intertan nail had slightly 
less pain at early postoperative mobilization compared to those operated with a SHS, 
but we found no difference at 12 months. Regardless of fracture type, mobility, hip 
function, quality of life, and surgical complication rates were comparable for the two 
groups at 12 months.  
In simple two-part trochanteric fractures (3DSHU,,) the SHSs had a lower 
complication rate compared to IM nails one year postoperatively (2.4% and 4.2% for 
SHS and IM nail, respectively, p = 0.001). Only minor, and clinically insignificant 
differences between the groups were found for pain, patient satisfaction, and quality of 
life.  
In 3DSHU,,,, conversely, we found that the patients operated with an IM nail had a 
significantly lower failure rate compared to the SHS one year postoperatively (3.8% vs. 
6.4%, respectively, p = 0.011). Small differences regarding pain, patient satisfaction, 
quality of life, and mobility were also in favor of IM nailing.
&RQFOXVLRQV: 
Pain, function, quality of life, and reoperation rates were similar for the Intertan nail 
and the SHS in trochanteric and subtrochanteric fractures 12 months postoperatively.  
Data from our hip fracture register, however, favored the SHS in simple two- part 
trochanteric fractures, whereas IM nails had the lower complication rate and better 
clinical results in reverse oblique and subtrochanteric fractures. Accordingly, a 
differentiated treatment algorithm based on fracture type could be considered.
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5. Introduction and background 
5.1 Overview, hip fractures in general  
Hip fractures are common in the elderly, and for the individual patient a hip fracture 
may cause short and long term pain, impaired function, and reduced quality of life. Up 
to one half of the patients may not regain their prefracture walking capacity, and 
independent living may no longer be possible (1). The mortality after hip fractures is 
high, and the overall one year mortality for the elderly patients with hip fractures is 
approximately 20-25% (2,3). 
Because of the large numbers of fractures, and patients with advanced age, hip 
fractures also represent a major challenge to hospitals, other health care providers, and 
society. In addition, due to the aging of the population the next decades, the numbers 
of hip fractures and health care expenses are expected to increase considerably. This 
will further enhance the focus on prevention of fractures and optimization of the 
treatment. The importance of a well-performed surgical treatment in hip fracture care 
is undisputable, however, treating the patients from a holistic point of view is probably 
even more important in order to improve the overall outcome for these patients. 
Today, approximately 10000 hip fractures occur in Norway each year (4). Compared 
to the Norwegian estimates, however, the future demographic changes, and the 
increased burden on health care systems, will be even more challenging in other 
countries and continents. By the year 2050 up to 6.3 million hip fractures have been 
estimated each year world-wide (5). 
The large individual and societal consequences of hip fractures world-wide, 
considering the perspectives of an aging population in particular, also underlines the 
need for persistent and increasing research on hip fracture care in the future.  
The main focus of this thesis has been on the trochanteric and subtrochanteric hip 
fractures and their surgical treatment. 
13 
5.2 Classification of hip fractures 
Hip fractures are classified into different subgroups depending on the anatomical 
localization and degree of fracture complexity ()LJD). There are two main categories, 
the intracapsular (femoral neck) fractures and the extracapsular (trochanteric and 
subtrochanteric) fractures. 
 
These are further divided into sub-categories. 
According to data in the Norwegian Hip Fracture 
Register (NHFR) approximately 60% of hip 
fractures are femoral neck fractures, 35% are 
trochanteric fractures, and 5% are 
subtrochanteric fractures (6). Different 
classifications have been used to describe hip 
fractures. In the NHFR we are using the Garden 
classification (7) for femoral neck fractures and 
the AO/OTA classification (8) for trochanteric 
fractures )LJE. 
)LJD Classification of hip fractures.Intracapsular = 
femoral neck fractures. Extracapsular = pertrochanteric, 
intertrochanteric, and subtrochanteric fractures.  
)LJE AO/ OTA classification of 
trochanteric hip fractures. 
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Subtrochanteric fractures are classified as fractures with the main fracture line below, 
but within 5 cm from the lesser trochanter ()LJD). The classification of hip fractures 
into subgroups is fundamental to be able to define specific treatments for specific 
fractures, as well as to compare and interpret results in research.  
5.3 The surgical treatment of hip fractures 
In general, hip fractures require surgical treatment, but the treatment and implant 
selection varies, depending on the fracture type (classification). For instance, the 
treatment of an undisplaced femoral neck fracture is totally different from the 
treatment of a displaced subtrochanteric fracture. Whereas femoral neck fractures are 
usually treated with a hip arthroplasty (elderly patients with displaced fractures) or 
screw-fixation (in undisplaced fractures or in young patients) trochanteric and 
subtrochanteric fractures are usually treated with a sliding hip screw (SHS) or an 
intramedullary (IM) nail )LJ Other implants are also used, but less frequently.  
Screws or hemiarthroplasty Intramedullary nail or sliding hip screw
Femoral neck fractures: Trochanteric or subtrochanteric fractures:
There are important differences in biomechanics and surgical exposure for a SHS and 
an IM nail. The6+6 is a combination of a screw and plate system, where the screw 
within the femoral head and neck fragment is connected through a barrel to a plate 
)LJCommon treatment options in hip fracture surgery 
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placed onto the lateral surface of the femur (outside the bone), allowing some fracture 
impaction (“sliding” hip screw) over the fracture site at mobilization ()LJDDQGE  
 
              
 
 
This surgery is usually performed with an open approach through skin and muscle 
onto the lateral surface of the femur. A trochanteric stabilizing plate (TSP) may be 
added to the SHS to enhance the stability for certain fracture types ()LJF The,0
QDLO, on the other hand, is an implant where both the femoral head-neck screw and the 
c) Different trochanteric stabilizing plates (TSPs) used 
together with a sliding hip screw 
  a) Schematic           b) Postoperative x-ray 
)LJ The sliding hip screw 
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nail itself are placed within the bone (“intramedullary” means 
nail in the central canal of the femur) ()LJ). Also this implant 
allows some controlled impaction at the fracture site along the 
axis of the femoral head and neck screw, which may be an 
advantage for some trochanteric fractures. An IM nail can 
usually be applied performing a closed reduction of the fracture 
and a mini-invasive surgical approach to insert the implant, 
requiring less surgical dissection of soft tissues around the 
fractured bone.
5.4 The literature and current controversies  
The SHS is the best documented implant in the treatment of 
trochanteric hip fractures, and in several studies the SHS has 
also been associated with the better results in terms of complication and reoperation 
rates, compared to IM nails (9,10,11). This is particularly the case for the two-part 
trochanteric fractures (AO/OTA type A1), and for studies performed some years ago. 
In addition, the SHS has been the less expensive implant. Nevertheless, despite the 
SHS frequently being considered as the gold standard in most trochanteric fractures, in 
some countries, e.g. the U.S., there has been a recent trend towards a more widespread 
use of IM nails in these fractures. This development has, however, not been supported 
by better results for IM nailing in the literature (12,13,14). Historically, IM nails have 
resulted in more intra- and postoperative peri-implant femoral fractures compared to 
the SHS, and whether, or to which extent, modern IM nails decrease the number of 
such complications needs to be proven. In a recent review by Bhandari et al.(15), the 
change of postoperative femoral fracture rates after Gamma-nailing over time was 
assessed, and a trend towards less and finally no difference between the SHS and the 
Gamma nail was found in more recent studies. Therefore, interpreting earlier RCTs 
and meta-analyses with caution was recommended. However, no studies published 
after 2005, or studies on other types of IM nails, were included in their review. Cutout 
of the implant in the femoral head, the most common surgical complication in these 
fractures, and all other general and surgical complications, have been equally 
)LJ An 
intramedullary nail 
(In this case a TFN, 
Trochanteric fixation 
nail, from Synthes)
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distributed between the two groups of implants according to updated meta-analyses 
(9,10).  
The subgroup of intertrochanteric (“reverse oblique”, AO/OTA type A3) and 
subtrochanteric fractures is usually assessed as highly unstable, and for several reasons 
the SHS is often considered inappropriate for the treatment of these fractures. The 
mechanical forces in the subtrochanteric area are high, and the sliding hip screw with 
its lateral and extramedullary position is, at least from a biomechanical and theoretical 
point of view, considered inferior to an IM nail. In addition, due to the sliding 
mechanism parallel to a reverse oblique fracture line, the SHS without a TSP is 
considered inappropriate for the reverse oblique fracture type in particular. Better 
biomechanical properties and lower failure rates are highlighted by several authors 
who recommend IM nailing as the treatment of choice in such fractures (16,17,18,19). 
However, results are not unambiguous, and more favorable reoperation rates for the 
SHS have been reported in other studies (20,21,22). In Norway the SHS, preferably 
with an additional TSP, is still the most frequently used implant also for reverse 
oblique and subtrochanteric fractures. Adding a TSP may enhance fracture stability 
and prevent the medialization of the femoral shaft and thus justify the SHS also in 
these fractures. Several clinical studies have reported favorable results using this 
construct (23,24,25), and the ability of the TSP to resist dislocating forces causing 
excessive lag screw sliding and medialization of the femoral shaft has also been 
confirmed in biomechanical studies (26,27).  
There is no clear or undisputable conclusion in the literature as to which implant or 
treatment option is the best for trochanteric and subtrochanteric hip fractures. 
Frequently, the SHS and the IM nails are considered equivalent for the stable 
trochanteric fractures. For unstable pertrochanteric (AO/OTA type A3) fractures, 
however, and unlike Norwegian traditions, Kregor and colleagues from the Evidence-
Based Orthopaedic Trauma Working Group recommended that IM nailing should be 
the preferred treatment (17). Kuzyk and co-workers came to a similar conclusion for 
subtrochanteric fractures (28). Nevertheless, both review articles acknowledged 
limitations in the scientific documentation and stated that larger comparative trials 
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                            a) Schematic       b) Postoperative x-ray 
)LJ The Intertan nail  
were needed to give clear recommendations. This lack of evidence, and the remaining 
controversies regarding the implant selection for trochanteric and subtrochanteric 
fractures, was the main reason for conducting the different studies within the scope of 
this thesis. 
5.5 The Intertan nail  
The Intertan nail (TRIGEN INTERTAN intramedullary nail, Smith & Nephew, 
Memphis, Tennessee) was introduced in 2006 as yet another nail to treat these 
fractures (29). According to the manufacturer, the nail had improved biomechanical 
properties and was providing better rotational stability due to its anatomical shape and 
two interdigitating screws in the femoral head and neck fragment )LJDDQGE.  
 
         
 
It was argued that the implant also facilitated the possibility of controlled 
intraoperative compression of the fracture, and that its feathered tip was designed to 
prevent intraoperative and later femoral fractures from occurring. In biomechanical 
testing there had been a favorable resistance to cutout of the implant in the femoral 
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head compared to other nails (30), and the early clinical experience was promising. In 
theory, a more stable implant and mini-invasive surgery could have advantages, in the 
early postoperative phase in particular, compared to a potentially more unstable 
implant operated with an open procedure (the SHS). Less pain, better functional 
mobility, and possibly a shorter stay in hospital could be benefits if this hypothesis 
came true. Such improvements, however, would have to be confirmed in well designed 
clinical trials.
The gold standard in clinical research is the randomized controlled trial (RCT), and it 
was our first goalto assess in a large multicenter RCT whether the Intertan nail, 
compared to the SHS, really improved clinical results and reduced complication rates 
in patients with trochanteric and subtrochanteric fractures (Papers I and IV).  
However, not all scientific questions can be answered in RCTs.  
5.6 The Norwegian Hip Fracture Register  
There are some well known limitations to RCTs. Studies are often very time 
consuming, costly, and with limitations to the length of follow-up and number of 
patients included. Consequently, it may take a long time before results can finally be 
presented, and the lack of statistical power is a common problem. Therefore, some 
scientific questions are better answered in well designed register studies. In these 
studies, with larger numbers of patients included, we may detect small, but still 
clinically relevant differences between implants and surgical methods. In fact, unless 
large RCTs or meta-analyses of RCTs have been performed, register studies may be 
the only option to prove small differences regarding outcomes like complication and 
reoperation rates. Such considerations were the background for conducting the studies 
based on data from the Norwegian Hip Fracture Register in this thesis (Papers II and 
III). In simple two-part trochanteric fractures, differences in complication rates 
between SHS and IM nails are usually small, and secondly, the reverse oblique and 
subtrochanteric fractures are rather uncommon. In these situationsand for outcome 
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parameters like complication and reoperation rates in particular, register studies may 
provide the best available evidence.  
The NHFR was established in 2005, and based on reports from the operating surgeons 
data are collected on all acute hip fractures and reoperations nation wide. In addition, 
questionnaires regarding pain, patient satisfaction, and quality of life are sent to the 
patients 4, 12, and 36 months postoperatively (31). By the end of 2011, more than 
55000 acute hip fractures were registered in the NHFR. 
As data from the hip fracture register show, there is currently no consensus among 
Norwegian surgeons or hospitals regarding the implant selection for different 
trochanteric and subtrochanteric fractures. 
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6. Aims of the studies 
“The Intertan Study” (1)  
Paper I  
The aim of this randomized clinical trial was to assess whether treatment with the new 
Intertan nail results in less postoperative pain, a shorter length of hospital stay, or 
improved function for elderly patients with trochanteric and subtrochanteric fractures 
compared to treatment with the SHS. In addition, we wanted to assess complication 
and reoperation rates.  
Norwegian Hip Fracture Register Study (1) 
Paper II
The aim of this observational study was to compare reoperation rates, pain, and quality 
of life for patients treated with IM nails or SHSs in simple two-part trochanteric 
fractures (AO/OTA type A1) using data from the Norwegian Hip Fracture Register. It 
was of particular interest if our current strategy of treating these fractures with a SHS 
was supported by results from our register, or, on the contrary, if the results would 
support recent international trends towards a more frequent use of IM nails even in 
these fractures.  
Norwegian Hip Fracture Register Study (2) 
Paper III 
The aim of this second register based study was to analyze data from the Norwegian 
Hip Fracture Register on reverse oblique trochanteric (AO/OTA type A3) and 
subtrochanteric fractures, and to assess any difference in pain, satisfaction, quality of 
life, or reoperation rates for patients treated with IM nail or SHS. For this group of 
fractures the implant selection has been even more controversial. Our treatment policy 
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of most frequently using a SHS for these fractures has been questioned, and this study 
could add valuable information to the relatively sparse literature on this topic. 
“The Intertan Study” (2) 
Paper IV 
As a part of “The Intertan Study” our aim with this study was to assess a similar set of 
outcome parameters (as in Paper I) for the reverse oblique intertrochanteric and 
subtrochanteric fractures in a separate subgroup analyses. In-depth analyses of these 
fractures, similar to the second NHFR study, could also add important information and 
possibly indicate whether our treatment policy of using a SHS (with or without a TSP) 
in these fractures is still acceptable or not. To the best of our knowledge, this was the 
first RCT comparing a SHS to an IM nail for the reverse oblique fracture type. 
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7. Patients and methods 
Papers I and IV 
Patients and fractures 
Papers I and IV were based on “The Intertan Study”, a multicenter study involving 
patients from five Norwegian hospitals (Levanger Hospital, Vestfold Hospital, 
Akershus University Hospital, Diakonhjemmet Hospital, and Haukeland University 
Hospital). Follow-up and outcome variables were similar for the two studies. 684 
patients older than 60 years with trochanteric and subtrochanteric fractures were 
included in this study from February 2008 until February 2009 (341 Intertan, 343 
SHS) 3DSHU,. Of these, 159 patients with inter- and subtrochanteric fractures were 
also included in the in-depth study of 3DSHU,9 (78 Intertan, 81 SHS). Approximately 
30% of the patients sustaining a hip fractures are cognitively impaired, therefore it was 
important to include also this group of patients. Patients with pathologic fractures were 
excluded, and patients sustaining a contralateral fracture during follow-up were not 
included a second time. Trochanteric fractures were classified by an independent 
radiologist according to the AO/OTA classification in A1-, A2-, and A3-fractures with 
subgroups )LJE Fractures below, but with the main fracture line within 5cm from 
the lesser trochanter, were classified as subtrochanteric )LJD 
Surgical implants  
The Intertan nail was used in a short or a long version with distal locking. All nails had 
two integrated screws into the femoral head-neck fragment )LJ Two different SHS 
implants were used, the Compression Hip Screw (Smith & Nephew, Memphis, 
Tennessee,) and the Dynamic Hip Screw (Synthes, Basel, Switzerland). An optional 
trochanteric stabilizing plate (TSP), either as an integrated part of the SHS or added as 
a separate devise onto the SHS, was used when indicated ()LJF). With only minor 
differences in design, and similar biomechanical principles for the two sliding hip 
screws and their TSPs, they were considered as one group.      
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The study protocol recommended the use of long nails and a SHS with an additional 
TSP in reverse oblique trochanteric (AO/OTA type A3) and subtrochanteric fractures, 
butthese guidelines were not consistently followed by the surgeons. Consequently, in 
the subgroup analyses (Paper IV), 57 (70 %) out of 82 patients operated with a SHS 
had an additional TSP, and 51 (66%) out of 77 of patients operated with a nail, 
received a long nail in this subgroup of fractures. 
The SHS, with or without a TSP, was the standard treatment for all trochanteric and 
subtrochanteric fractures at the participating hospitals before we started the study. 
Therefore, a training program for the use of the Intertan nail was carried out before 
patients were enrolled. 
Follow-up and outcome measures 
With a special focus on the early postoperative rehabilitation, the in-hospital course of 
the patients was followed closely, including assessment of postoperative pain (Visual   
analogue scale, VAS) and functional mobility (timed Up & Go (TUG-) test (32)), 
complications, blood loss, and length of hospital stay. In addition, postoperative x-rays 
were examined for fracture reduction and implant position, including the tip-apex 
distance (TAD) as described by Baumgaertner (33). Clinical examination, including 
the Harris hip score (HHS) (34) ($SSHQGL[) and filling out an EQ-5D questionnaire 
(35) ($SSHQGL[), were scheduled at 3 and 12 months postoperatively. Depending on 
local preferences in each hospital, the clinical examination of the patients was carried 
out by a physician or a physiotherapist, or in collaboration between these professionals. 
In some hospitals, also a study nurse was involved.   
Early postoperatively pain, functional mobility, and length of hospital stay were the 
primary outcomes in this study. Pain-scores and TUG-test performance were measured 
at all follow-up visits. Secondary outcomes were the patients’ living conditions, 
walking ability, hip function (HHS), quality of life (EQ-5D), complication and 
reoperation rates, and mortality. In addition, x-rays were assessed for the TAD, 
fracture shortening, medialization of the femoral shaft, changes in the femoral neck-
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shaft angle, and for any disturbance of the fracture healing 3 and 12 months 
postoperatively $SSHQGL[. 
Statistical methods 
5DQGRPL]DWLRQThe patients were randomly allocated to one of the two implants 
using sealed, opaque, and consecutively numbered envelopes. Block randomization 
with varying block sizes unknown to the surgeon was used to ensure near-equal 
treatment numbers within each hospital.  
6DPSOHVL]H A difference in VAS scores of 10 points was considered a clinically 
relevant difference. 63 patients in each group were required to have an 80% chance of 
detecting such a difference in VAS scores with a 5% significance level with an 
assumed standard deviation (SD) of 20. There is to our knowledge no well-defined 
clinically significant difference for the TUG-test. However, 112 patients would be 
required in each group to detect a mean difference of 3 seconds (10% of 30 seconds) 
with an assumed SD of 8 seconds. To detect a reduction in the length of hospital stay 
of 1 day (SD 3), 142 patients would be needed in each group. A difference in 
reoperation rates of 5% versus 7% would require more than 2000 patients in each 
group to detect a significant difference with 80% power and p <0.05. Accordingly, this 
study was not designed to have reoperation rate as a primary outcome. A high 
mortality rate, a high number of cognitively impaired patients, and an expected high 
dropout rate were considered when the sample size for the study was determined. Thus, 
assuming a one-year an attrition rate of up to 40%, we aimed to recruit at least 500 
patients in the study within one year.  
To test for group differences, the Pearson chi-square test was used for categorical 
variables and the Student’s t-test was used for continuous variables. Due to an uneven 
distribution between the two groups, linear regression analyses with adjustment for the 
differences in cognitive impairment and surgeons’ experience were performed. We 
also performed additional analyses for primary outcomes after excluding the 
cognitively impaired patients. The results were analyzed according to the intention-to-
treat principle, where patients remained in the group to which they were allocated at 
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baseline. The plan was to examine all patients the 5th postoperative day, but this was 
not possible in all cases. Accordingly, the in-hospital pain and TUG-test results were 
analyzed with adjustment for differences in the time of patient examination in linear 
regression analyses. Finally, Kaplan-Meier analysis was used to estimate one year 
mortality, and the log-rank test was used to test for statistically significant differences.  
P-values less than 0.05 were considered statistically significant (two-sided tests). 
Papers II and III 
Patients and fractures
The papers II and III were based on patients of all ages operated for subgroups of 
trochanteric and subtrochanteric fractures recorded in the Norwegian Hip Fracture 
Register $SSHQGL[. By the end of 2010, 47,178 primary operations for hip 
fractures operated at 58 different Norwegian hospitals had been reported to the register. 
Of these 17,148 were primary operations for trochanteric (n = 14,822) and 
subtrochanteric (n = 2,326) fractures. Only fractures treated with a SHS or an IM nail 
were included in our studies, and pathological fractures were excluded. The 
classification of fractures was based on the same principles as in Papers I and IV 
(AO/OTA classification).  
In 3DSHU,,, 7,643 operations for simple two-part trochanteric fractures (AO/OTA 
type A1, Fig 1b) were analyzed. The average age of the patients was 81.7 years, and 
71% were women.  
In 3DSHU,,,, 2,716 operations, 390 intertrochanteric (reverse oblique trochanteric, 
AO/OTA type A3, Fig 1b) and 2,326 subtrochanteric fractures (Fig 1a) were analyzed. 
The average age of the patients was 79.3 years, 75% were women.  
Implants 
The NHFR has detailed information about the operations performed and the implants 
used. Implant dimension and brand name of plates, screws and nails are usually known 
in detail.  
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In 3DSHU,,83% (n = 6355) of the operations were performed with a SHS. A 
trochanteric stabilizing plate was added in 8% of these cases.  Of the remaining nailing 
procedures (n = 1288), 96% were performed with a short nail. Long IM nails were 
used in only 4% of the nailing procedures. 
The SHS was the most common implant also in 3DSHU,,, and comprised 66% out 
2,716 operations (1,792 SHS and 924 IM nails). For implant specific subgroup 
analyses, we also divided the implants into 4 different categories; the “plain” SHS, the 
SHS with an additional TSP, and short and long nails. An additional TSP was used in 
63% (n = 1120) out of the 1,792 SHS operations, and long nails were used in 74% (n = 
688) of the nailing procedures. We did not perform any analyses based on brand 
names in either of the two papers. 
Follow-up and outcome measures 
Using a standardized questionnaire at 4, 12, and 36 months postoperatively, the 
patients or their care-givers were asked to answer questions regarding different 
outcome measures, such as quality of life (EQ-5D), pain (VAS), patient satisfaction 
(VAS), and general health status (VAS). An evaluation of similar outcome measures 
preoperatively was also performed in retrospect at the 4 months follow-up. In addition, 
any reoperation, including type of operation and the cause of the reoperation, was 
reported to the NHFR by the operating surgeons. 
All patients in study II and III were observed for any reoperation until December 31, 
2010 (follow-up 0-6 years), and in 3DSHU,,,, the questionnaire regarding pain and 
quality of life was sent to all living patients during follow-up from 2005 to 2010. In 
3DSHU,,, however, all patients operated with IM nails or a SHS with a TSP received a 
questionnaire from 2005 to 2010, but for patients treated with a simple SHS, all 
patients in 2005, 2006, and 2010, but only a randomly selected group of patients in 
2007 to 2009, were asked to answer the questionnaire.  
The reoperation rate was the primary outcome in both studies. In addition, quality of 
life issues, including the mobility (ability to walk), pain, and patient satisfaction were 
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secondary outcomes. The EQ-5Dindex score is the utility score derived from the 5 
dimensions (mobility, degree of self care, ability to perform usual activities, 
pain/discomfort, and anxiety/depression) in the EQ-5D questionnaire. This was 
calculated for all patients, 0 indicating a situation similar to death, 1 being the best 
possible score for quality of life. 
Statistical methods 
Similar statistical methods were used for the two register based studies. To test for 
group differences for categorical outcome variables like reason for reoperation, type of 
reoperation, and walking ability, we used the Pearson chi-square test. The Student’s t-
test was used for analyzing continuous outcome variables like pain, patient satisfaction, 
and EQ-5Dindex score. In the survival analyses, the endpoint was any reoperation, and 
Kaplan-Meier analyses were used to determine the proportion of reoperations after one 
and three years (and mortality in Paper II). The log-rank test was used to test for 
statistical significance of differences in survival between the two groups. A multiple 
Cox regression model with adjustment for potential confounding by age, gender, ASA-
class, and cognitive impairment (and fracture type in Paper III) was used to assess the 
relative risk of reoperation for the two treatment groups. The National Population 
Register provided information on deaths and emigrations. P-values less than 0.05 were 
considered statistically significant (two-sided tests). To adjust for potential differences 
in baseline characteristics between the two groups, additional analyses using the 
propensity score method were performed in Paper III.
Source of funding (Papers I – IV)
“The Intertan Study” was supported by Smith & Nephew, but the company had no 
influence on the study protocol, performance of the study, data analysis, or the 
presentation of the results. I also received a grant from the Regional Health Board of 
Western Norway to complete the work on this multicenter trial and for further hip 
fractures research included in my PhD thesis. The Norwegian Hip Fracture Register is 
funded by the same Regional Health Board. 
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8. Summary of results  
Paper I 
Overall, pain, function, and reoperation rates were similar for the Intertan nail and the 
SHS in trochanteric and subtrochanteric fractures 3 and 12 months postoperatively in 
this RCT. Patients treated with the Intertan nail had slightly less pain in the early 
postoperative period, and because of less blood loss fewer patients received a blood 
transfusion in that group. However, this did not influence in-hospital complication rate 
or length of hospital stay, which was also similar for both groups. This study also 
confirmed that postoperative femoral fractures remains a problem even with modern 
nail designs, as more peri-implant fractures occurred in the Intertan group. 
Paper II 
Based on data from the NHFR, we found that IM nailing of simple two-part 
trochanteric fractures (AO/OTA type A1) had a significantly increased risk of 
reoperations within one year postoperatively compared to operations with a SHS 
(4.2% and 2.4% reoperation rate for IM nail and SHS, respectively , p = 0.001). At 
three years the percentages were 7.1% and 4.5% for IM nail and SHS, respectively. 
Only minor and clinically irrelevant differences between the groups were found for 
other outcome measures (pain, patient satisfaction, and quality of life). 
Paper III 
This observational study compared results after operations with SHSs (n = 1792) and 
IM nails (n = 924) for reverse oblique (OA/OTA type A3) and subtrochanteric 
fractures. One year postoperatively patients with reverse oblique trochanteric and 
subtrochanteric fractures operated with a SHS had a higher reoperation rate compared 
to those operated with an IM nail (6.4% and 3.8%, respectively, p = 0.011). This 
difference also persisted and even increased three years postoperatively (reoperation 
rates of 10.2% and 6.7%, respectively). Adjusted for age, gender, ASA-class, cognitive 
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impairment, and fracture type there was a 43% increased risk of having a reoperation 
after operation with a SHS compared to an IM nail. Small differences regarding pain, 
patient satisfaction, quality of life, and mobility were also in favor of IM nailing.  
Paper IV 
In this second part of “The Intertan Study”, comparing the SHS and an IM nail for 
reverse oblique trochanteric (AO/OTA type A3) and subtrochanteric fractures, we 
found no significant difference regarding pain, function, quality of life, or 
complication and reoperation rates between the two treatment groups. The estimated 
blood loss and number of patients receiving blood transfusions, however, were slightly 
higher in the SHS group. 
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9. Discussion  
9.1 Methodological considerations 
Papers I and IV  
The randomized controlled trial represents the gold standard in clinical research. 
Confounding factors should be ruled out through randomization, and the only 
difference between the groups should theoretically be one single variable under 
examination. Compared to other RCTs on fracture treatment, the number of patients 
included in our study was a major strength. To our knowledge, this is the largest 
published series of its kind, and for the subgroup of reverse oblique and 
subtrochanteric fractures, it is the only RCT reported in the literature comparing SHS 
and IM nail. In addition, due to the multicenter design, many different surgeons and 
several hospitals participated in the study, thereby closely resembling a real-life setting. 
This also increases the external validity of our study.  
However, despite obvious advantages, there are also some well known limitations to 
RCTs, our studies included; 
1XPEHURISDWLHQWV Even in our study with almost 700 patients included, we did not 
have the statistical power to draw valid conclusions with regard to differences for rare 
outcomes such as surgical complications and reoperations. For example, to detect 
statistically significant differences in reoperation rates, either the difference in number 
of events between the two groups have to be large, or a huge number of patients have 
to be included. None of these conditions were satisfactorily met in our study.  
%OLQGLQJ Ideally, both patients and follow-up examiners should be blinded to the 
treatment. However, in this large multicenter study we considered the ideal solution 
difficult to obtain, in particular since this was a study comparing surgical implants and 
operative methods including different skin incisions. In addition, masking of x-rays 
and patients would be very time-consuming, and an extra set of independent reviewers 
in five different hospitals would have been required for follow-up assessments.  
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)ROORZXSFor RCTs in general, achieving a high proportion of long term follow-up 
can be a challenge, and for elderly patients frequently living in nursing homes in 
particular. Accordingly, assessing long term effects or long term differences between 
treatment options in RCTs can be difficult. This was also a challenge in our study, 
however, long term losses to follow-up were equally distributed between the two 
groups. In addition, we had a main focus on in-hospital pain and function in the early 
postoperative period. Still, we were not able to examine all patients the same 
postoperative day. This could have influenced our results, but using a multiple linear 
regression we could adjust for differences in day of examination. 
9DOLGLW\ Depending on details in study design, conducting a RCT does not guarantee 
that the results found in one study are necessarily applicable to others. For instance, 
differences in patient selection (inclusion or exclusion criteria) and surgeons’ 
qualifications may reduce the external validity of an otherwise well performed study. 
In the present study, and despite the random allocation of patients, the groups were 
slightly different with regards to patients’ cognitive status and the experience of the 
surgeons. In our statistical analyses, however, we were able to adjust for these 
differences. Further, by conducting a multicenter study, and including a large number 
of patients, we tried to minimize the risk for any potential bias between the groups. To 
a certain degree, the large number of patients also compensate for limitations due to 
losses to follow-up, and the inclusion of demented patients frequently unable to 
respond adequately to different research questions. Thereby, we believe the results 
from our studies are also valid to others. However, the results do not necessarily apply 
to other types of IM nails.
33 
Papers II and III 
Despite being the gold standard, RCTs cannot answer all research questions. For 
instance, and as already described, RCTs may not have the statistical power to detect 
small, but still relevant differences in complication or reoperation rates. For such 
questions, and for long term follow-up, observational studies based on national 
registries, such as the Norwegian Hip Fracture Register, may have advantages.  
For three important reasons, at least, register-based observational studies were 
appropriate for our research question; whether to use a SHS or an IM nail in 
trochanteric and subtrochanteric fractures. First, in general, differences in outcome for 
the two implants are small, if at all existing. This is true even for complication and 
reoperation rates. Because of these small differences, and a limited number of patients 
included in randomized trials, even meta-analyses of randomized trials may struggle to 
prove any significant difference between the two implants (9). Observational studies 
including thousands of patients might be a better way to address this problem. Second, 
and mainly relevant for Paper III, some fractures are rather uncommon. Therefore, 
collecting enough patients in RCTs within a reasonable time frame might not be 
possible. Finally, results reflecting a national average of surgeons and hospitals may 
actually be more relevant and correct, compared to results from RCTs performed in 
selected centers and by dedicated and more experienced surgeons. These strengths also 
apply to our register-based studies presented in Papers II and III.  
Nevertheless, there are also some limitations to our register studies. Inherently, in a 
register-based study, patient or surgeon-related confounders not covered in the register 
data may influence the results. Further, fracture classification was performed by the 
individual surgeon, and the accuracy of the classification may therefore represent some 
uncertainty. Not surprisingly, the response rate from these often elderly patients is 
rather low, approximately around 50%. Even though we assume that surgical revisions 
are more consistently reported by the surgeons, the completeness of these data has not 
been validated. There is, however, no reason to believe that reoperation rates after the 
two different implants should be reported differently. Therefore, even though some 
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uncertainty regarding the absolute reoperation rates may exist, the differences between 
the implants should be reliable. Finally, IM nails and SHSs were assessed as two 
implant groups, and not as a series of different brands with minor differences between 
implants. Accordingly, our results represent an average for several implants within 
each group, and might not apply equally to each individual implant (brand).  
The major strength of these studies is the large number of patients included, and as 
patient characteristics regarding age, gender, average ASA-score, and cognitive 
function at baseline were similar for the two groups, a selection bias is less likely. A 
selection bias is also less probable as treatment policy and implant selection in our 
country usually is a matter of administrative decisions in each hospital, and less based 
on the surgeons’ individual preference. Accordingly, we believe our main findings in 
these studies are valid.
Overall, observational studies represent an important adjunct to RCTs, and for certain 
questions they may even provide the best available evidence (36). But still, and for 
reasons as mentioned above, results should be interpreted with caution. This also 
applies to our papers II and III.  
9.2 Results  
Papers I and IV 
Overall, we found comparable results for patients operated with Intertan nails and 
SHSs in the present study (Papers I and IV). The Intertan group had slightly less pain 
at early postoperative mobilization, but this difference was not reflected in better 
functional mobility or shorter length of hospital stay. Regardless of fracture 
classification, no differences in pain, function, quality of life, or complication rates 
were evident at 3 or 12 months follow-up. This is in line with most recent studies and 
meta-analyses (9,14,15,37,38), but finding similar results for the subgroup of reverse 
oblique and subtrochanteric fractures has to our knowledge previously not been 
published in any RCT (Paper IV).  
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For an individual patient a VAS pain score difference of 10 points is considered a 
clinical relevant difference (39). Although this may be interpreted differently at a 
group level, a difference of 4 points in the early postoperative phase, as in the present 
study, is probably of minor clinical relevance. The mean estimated blood loss was 80 
ml higher in the SHS group, but assessing “internal” blood loss after nailing is difficult. 
More patients in the SHS group received a blood transfusion, but we had no protocol 
for transfusing patients, and the hemoglobin level at the time of transfusion was not 
known. The difference in blood loss, or number of blood transfusions, did not seem to 
influence the length of stay or in-hospital complication rates. Therefore, the clinical 
significance of these differences is debatable.  
The timed Up & Go test (32) and the Harris hip score (34) are common outcome 
measures assessing function after hip fractures (40), and were both used in the present 
study. However, regardless of outcome measure used, we did not detect any significant 
difference in function between the two implant groups during follow-up. This is also in 
accordance with recent meta-analyses (9,10,41).  
Since the introduction of IM nailing in trochanteric 
fractures, peri-implant femoral fractures have been well 
known complications (42,43,44,45) )LJ But 
according to Bhandari et al. (15), assessing different 
generations of the Gamma-nail and postoperative 
femoral fracture rates over time, this should no longer 
be an issue with modern nail design and more 
experience. Nevertheless, the Cochrane review (9) still 
comes to a different conclusion and in a recent study on 
Intertan nails, 6% postoperative femoral fractures were 
found (46). In our study we had five postoperative 
femoral fractures (1.5%) in the Intertan group, all 
within the first three months. Only one postoperative 
fracture occurred in the SHS group, but the difference 
in postoperative femoral fractures was not statistically significant (p = 0.10). Still, this 
)LJA postoperative 
femoral fracture at the tip of 
an Intertan intramedullary 
nail. 
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)LJ The tip-apex distance (TAD) according to 
Baumgaertner; The sum of the distance between the 
tip of the nail/screw and the apex of the femoral head 
in the frontal and the lateral plane (adjusted for 
magnification). 
implies that the problem with fractures around the tip of IM nails has not been 
completely solved.  
So far, no consistent difference in cutout rates between 
IM nails and SHS has been found in randomized trials 
(9). In a biomechanical study comparing the Intertan 
nail to other nail designs favorable results in terms of 
cutout were obtained for the Intertan nail (30). 
However, in a prospective study with one year follow 
up, Rücker et al. (47) reported 2 cutouts in 48 patients 
operated with the Intertan nail. In the present study, 
cutout was the most common cause of failure of the 
osteosynthesis regardless of type of implant, and we 
found no significant difference between the treatment 
groups )LJ  
It is well known that poor reduction and implant 
position give a poor prognosis in hip fracture 
treatment (33,48,49,50,51). In the 
present study, cutout and other 
surgical complications were 
associated with a higher tip-apex 
distance (TAD) )LJ, poor 
reduction, or reduction more into 
varus, but independent on type of 
implant. Accordingly, an increased 
focus on surgical perfection, rather 
than implant selection, will 
probably best address this 
problem. Fewer patients in the 
Intertan group had a 
medialization exceeding 5 mm, 
)LJ A sliding hip screw 
with a “cutout” of the head-
neck screw through the 
femoral head. 
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probably because of the intramedullary position of the nail, providing a solid 
resistance to excessive sliding along the axis of the lag screw. The increased 
medialization for the SHS group could not be prevented by the TSP, but our data does 
not allow us to quantify to which extent a TSP still may have helped. Despite 
radiographic differences in femoral neck-shaft angle, shortening, tip-apex distance, 
and medialization, no difference in pain, function, or surgical complication rate 
between the two groups was evident. 
The results presented above refers to overall results for all patients and all fracture 
types in our RCT (n = 684, Paper I), but practically the same results and conclusions 
also applies to the fractures assessed in our subgroup analysis (Paper IV). However, 
due to fewer patients in that study (n = 159), the statistical power is of course less.  
We are not aware of any RCT comparing the use of a SHS (including a TSP) with IM 
nailing in patients with inter- and subtrochanteric fractures, but two RCTs (52, 53) 
comparing an IM nail to other extramedullary implants in intertrochanteric fractures 
are reported in the Cochrane Database Review (9). One study found a higher 
reoperation rate for patients treated with a Dynamic Condylar Screw compared to the 
Proximal Femoral Nail (52), whereas one study comparing patients operated with a 
blade plate or a Gamma nail found no difference in reoperation rates (53). These 
studies, however, included only small numbers of patients (n = 39 and n = 26, 
respectively). Contradicting findings were also reported for patients with 
subtrochanteric fractures, comparing either a 95º blade plate (54), or the Medoff 
sliding plate (55,56) to an IM nail. According to our study, and recognizing some 
limitations regarding statistical power, the SHS (including a TSP) seems to be a valid 
option also in these fractures. No major differences were found for most clinically 
relevant outcomes. Finally, we found no significant difference between the groups 
regarding the surgical time. 
It is frequently argued that nailing is an easy and quick procedure, and that it is 
applicable to all types of trochanteric and subtrochanteric fractures. This might be 
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correct, but based on the results from the present study it might also be argued that 
even the SHS is applicable to all kind of trochanteric and subtrochanteric fractures.  
Papers II and III 
3DSHU,, Our main finding was a higher rate of complications and reoperations after 
IM nailing compared to SHS operations in simple two-part trochanteric fractures. 
Reoperation percentages at one year of 2.4% and 4.2% for SHS and IM nail, 
respectively, were comparable to other reports on trochanteric fractures. In line with 
our results, one recent meta-analysis of randomized trials concluded that the failure 
rates after IM nailing in stable trochanteric fractures were higher than failure rates 
after using a SHS, and IM nailing of these fractures could not be recommended (57). 
Our reoperation rates were slightly higher than those reported for stable fractures in 
that review, but lower than reported in other studies where stable and unstable 
fractures have not been separated (11,44,45). Even though absolute numbers of 
reoperations vary among studies, the consistent overall difference in favor of the SHS 
seems to persist. Postoperative femoral fractures rates were high using the first 
generations of IM nails (58,59,60,61). Therefore, reporting failure rates after IM 
nailing including nails no longer in use, may distort the results in updated reviews 
(9,10,62). This problem has already been discussed referring to the study on Gamma 
nails by Bhandari et al.(15). However, our data include only recent generations of 
implants, and therefore indicate that reoperation rates continue to be higher after IM 
nailing compared to the SHS in simple two-part trochanteric fractures. 
Secondly, we found no difference in pain or quality of life between the two implant 
groups during follow-up. The assessment of pain for patients with hip fractures has not 
been standardized, and several outcomes for pain have been reported in the literature 
(9,41). Therefore, comparing results is difficult. Nevertheless, regardless of implant 
and outcome measure used, and in accordance with our results, recent meta-analyses 
report no major difference in pain between implants and operative methods in 
trochanteric fractures (57). Our finding of “no difference” in the reported quality of 
life between the implants using the EQ-5Dindex score indicates that the difference in 
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reoperation rates was not enough to influence the patients’ perception of quality of life. 
One year postoperatively, however, more patients in the IM nail group rated their 
mobility and ability to perform usual activities with the best score. The differences 
were minor and temporary, but still, these EQ-5D dimensions describe important 
factors for patients to maintain their independency. We are not aware of any other 
study assessing quality of life using the EQ-5D-questionnaire in simple two-part 
trochanteric fractures. However, the most updated and comprehensive review of RCTs 
comparing SHSs and IM nails in trochanteric fractures concluded that there was no 
difference in terms of quality of life issues like pain, walking ability, or the number of 
patients regaining their prefracture level of independency after trochanteric fractures 
(9). 
3DSHU,,,Treating reverse oblique and subtrochanteric fractures with a SHS is by 
some authors considered inappropriate, in particular due to biomechanical 
considerations (17,19,63). However, the evidence in the literature is sparse and 
conflicting, and the debate whether to use a SHS or a nail in these fractures has not 
come to a final or indisputable conclusion.  
Our reoperation rates of 3.8% and 6.4% at one year for IM nails and SHS, respectively, 
are in the lower range compared to most other studies on reverse oblique and 
subtrochanteric fractures (20,44,55,64,65,66,67,68), and significantly higher failure 
rates, for the SHS in particular, have been reported in some studies (16,54,69). In a 
retrospective review of 55 patients with reverse oblique fractures operated with 
different types of implants over a 10 year period, Haiducewych et al.(16) reported a 
failure for 9 out of 16 patients operated with a SHS (56%). However, what we 
consider mandatory for the reverse oblique fractures, no TSP was used in their 
operations. Other implants were also associated with high failure rates in the same 
study, but due to a retrospective study design and a small number of patients, 
conclusions on failure rates and implant selection based on that study alone should be 
drawn with caution. Brammar and colleagues (21) found a considerably lower overall 
fracture healing complication rate of 9% in a review of 101 reverse oblique 
trochanteric fractures, and no statistically significant difference in reoperation rates 
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between SHS and IM nail was found in that study. More favorable complication rates 
for the SHS have also been reported in other studies (20,24,67).  
The additional use of a TSP (in 63% of our SHS-operations), for the reverse oblique 
fracture type in particular, may to some extent account for the lower rate of 
reoperations in our study. However, we had no x-rays available for initial fracture 
classification or later follow-up, and therefore, assessing the exact significance of the 
TSP in this register study was not possible. In addition, clinical data recorded in our 
hip fracture register are limited, and a randomized controlled study design would 
probably be the best way to assess any usefulness of the TSP. Recent improvements in 
implant design, and surgeons becoming more aware of surgical pitfalls in treating 
these fractures, may also have had a positive impact on failure rates. Incomplete 
reporting is another possible explanation for our rather low reoperation rates. In 
addition, as some elderly, demented, or frail patients may have been considered 
unsuitable candidates for further surgery, we might suspect the actual failure rates to 
be higher than our reoperation rates indicate. Therefore, the difference in reoperation 
rate between the two implants is probably more important than the absolute numbers. 
We may have underestimated the reoperation rates, but any under-reporting of 
reoperations should most likely be similar for the two groups.  
Historically, a high rate of peri-implant fractures has been a major concern after IM 
nailing for trochanteric fractures. In the present series of 924 patients treated with IM 
nails only two patients were reported with a second femoral fracture around the 
implant during a follow-up of 12 months. This is in line with the findings by Bhandari 
et al.(15), but such a low rate of peri-implant fractures might also represent an under-
reporting of these injuries to the register. However, as suggested by Bhandari and 
coworkers, improvements in operative technique and implant design could be other 
reasonable explanations. Finally, the frequent use of long IM nails (74%) in the 
present study may have prevented some peri-implant fractures. 
Due to a large number of patients in the present study, also small differences in pain, 
patient satisfaction, and EQ-5Dindex score reached statistical significance. The clinical 
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relevance of these minor differences, though, is debatable. A difference in VAS pain 
score of 3-4 points for the individual patient is not clinically relevant (39), but at a 
group level, such a difference should not be neglected. Similar, statistically significant 
differences regarding patient satisfaction within the first year cannot be ignored, but 
the importance of a statistically non-significant difference of 0.02 in the EQ-5Dindex 
score at one year in our study should not be overemphasized. Still, with a similar level 
of mobility at baseline, the patients’ self-assessment of significantly better mobility in 
the IM nail group 4 and 12 months postoperatively is an important finding and very 
relevant for this group of patients. 
Less pain in the IM nail group may be a result of mini-invasive surgery and/or better 
stability of the implant in the initial postoperative phase, whereas long term 
differences could be due to more local pain from protruding hardware or more 
secondary fracture displacement and malunions in the SHS group. Detailed 
information on such issues is, however, not retrievable from our register data. Pain is 
most probably also influential on patient satisfaction and quality of life measures, and 
may to some extent explain the slightly superior results in favor of the IM nail for 
these outcomes. 
9.3 Interpretations  
Papers I and IV  
Describing our overall results might be straight forward, but the interpretation of these 
data is not equally simple. For instance, comparing one IM nail to the SHS does not 
mean that these results are applicable to all IM nails. Further, results obtained in our 
hands may not be reproducible by others. In the present study, we offer no answer to 
how much we would be willing to pay for slightly less blood loss and a reduced 
number of blood transfusions, assuming results and complication rates are otherwise 
similar. In addition, what is the actual importance of slightly less pain (4-5 points on a 
visual analogue scale) the first postoperative days (with a similar length of hospital 
stay)?  
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The interpretation of our data might be compared to the two different perceptions of 
)LJ.  
Looking at the same picture, some observers will 
probably see a black candle, whereas others will 
immediately see the white profile of two faces. Similar, 
the results from “The Intertan Study” can be interpreted 
in different ways. From our own perspective, we found 
no hard evidence in the present study to support a change 
in treatment policy for trochanteric or subtrochanteric 
fractures, and the SHS has remained our implant of 
choice. However, based on the same results, it is also 
possible to come to a different conclusion. One might argue that it has finally been 
proven that modern nails have no more complications than the SHS, and that the 
overall results in the present study is actually in favor of the IM nail. Accordingly, the 
discussion whether the SHS or an IM nail is the best implant for some or all of these 
fractures will continue. 
Improving outcome and reducing complication rates in these patients and fractures 
remains a challenge. To achieve a good outcome, our results also emphasize the 
importance of surgical perfection, and optimizing fracture reduction and implant 
position is probably more important than the choice of implant. Finally, the 
interpretation of different outcome measures must also take study limitations and 
power calculations into account. This should not be forgotten. 
Papers II and III  
3DSHU,,Only contemporary implants used between 2005 and 2010 were studied, and 
our main finding was a significantly higher rate of reoperations after IM nailing 
compared to the SHS in simple two-part trochanteric fractures. Our study had some 
limitations, but with similar baseline characteristics for the two groups, and with 
results representing a national average of surgeons and hospitals, we suspect no major 
bias in the study. The results are also in accordance with recent meta-analyses of 
)LJ Rubin’s vase. 
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randomized controlled trials. Therefore, despite modern trends suggesting otherwise, 
the SHS still seems to be the best treatment for simple two-part trochanteric fractures. 
3DSHU,,, In this study, patients with reverse oblique trochanteric and subtrochanteric 
fractures operated with a SHS had a significantly higher reoperation rate compared to 
those treated with an IM nail. For similar reasons as mentioned above (Paper II), we 
believe this is a true difference caused by the implants and operative methods, and not 
to be explained by any bias between the groups. In addition, 4 and 12 months 
postoperatively we also found a small difference in pain, patient satisfaction, and 
quality of life (including walking ability) in favor of the nail. Based on these results, 
and as opposed to our current practice, a change in our treatment algorithm for these 
unstable fracture types could be considered. For those already treating these patients 
with an IM nail, the current study provides scientific evidence to support such an 
approach.  
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10. Conclusions 
In our randomized controlled trial (Papers I and IV), the TRIGEN INTERTAN nail 
was equivalent to the sliding hip screw in terms of pain, function, and complication 
and reoperation rates 12 months postoperatively, and these results were similar 
regardless of fracture type. Poor fracture reduction and implant position were clearly 
associated with increased complication and reoperation rates. Accordingly, to achieve 
a favorable outcome for these fractures and patients, the implant selection seems to be 
less important than attention to surgical details.  
In our register studies (Papers II and III), we found that the SHS seems to be the best 
implant with the least number of complications and reoperations for two-part 
trochanteric fractures (AO/OTA type A1). For the reverse oblique trochanteric 
(AO/OTA type A3) and subtrochanteric fractures, however, an IM nail seems to 
provide the best results. Corresponding changes in our current treatment strategy could 
be considered. 
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11. Future perspectives 
Despite years of experimental and clinical research, including improvements of 
implant design and surgical techniques, treating trochanteric and subtrochanteric 
fractures remains a challenge. Complications still occur, reoperations have to be 
encountered, and the patients frequently do not reach their pre-fracture level of 
function or independency. Accordingly, there is still room for improvements.  
An elderly osteoporotic lady falling at home represents the classic history of how hip 
fractures occur. Analyzing this simple history indicates how hip fractures may be 
prevented. Through measures addressing the problem of osteoporosis, the overall 
physical capacities of the elderly, the environmental factors in the patients’ home, and 
the increased risk of falling, a devastating hip fracture may to some extent be 
preventable. In addition, there are major challenges in how we take care of our elderly 
hip fracture patients after having performed our surgical treatment. 
In my opinion, the following topics should be emphasized in the future. 
11.1 Implementation of results 
The studies presented in this thesis, give some recommendations regarding the best 
treatment for selected trochanteric and subtrochanteric fracture types. For those 
treating these fractures differently today, a change in treatment policy could be 
considered. However, we should not forget that improving the care of hip fracture 
patients is more than just selecting a proper surgical implant. 
11.2 Prevention of hip fractures 
2VWHRSRURVLVis a global epidemic, in particular in the western world, and it is 
recognized as one major risk factor for sustaining hip fractures. Nutritional 
deficiencies or side-effects of other medical treatment may increase the problem of 
postmenopausal osteoporosis. Defining the best strategies to identify patients at risk, to 
motivate physicians to initiate screening for osteoporosis, and to start the correct 
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treatment before it is already too late, are challenges to be addressed in future clinical 
practice and research.
If elderly people didn’t fall, most hip fractures would have been avoided. Accordingly, 
introducing effective IDOOVSUHYHQWLRQSURJUDPVshould be one major goal in the 
prevention of hip fractures. However, as the reasons why patients fall are multi-
factorial, there is no easy way to prevent this from happening. A detailed analyses and 
more knowledge about falls; when, where, why, how, and for whom do they occur, is 
required to optimize the resources and to target interventions in the best way. Clear 
and well proven strategies should be developed, but to achieve these goals, major 
efforts and clear priorities from health care providers and the society will be required. 
Improving elderly patients’ balance, strength and general physical capacity would 
undoubtedly be beneficial, but how to achieve these goals, and to assess individual 
effects of different steps undertaken to reduce the number of falls needs to be explored.  
+LSSURWHFWRUV have been shown to be effective when they are used. Further research 
and product development should be encouraged, and methods to improve compliance 
should be established. 
11.3 Implants and surgical treatment 
6XUJLFDOWHFKQLTXH So far, no surgical implant or operative technique has been able 
to prevent surgical or mechanical failures in trochanteric and subtrochanteric fractures. 
And probably no implant or operative technique can compensate for poor fracture 
reduction or wrong implant position in the femoral head-neck fragment. Therefore, a 
structured educational program and continuous attention to surgical details in the 
treatment of these fractures might be a better way to improve results, as compared to 
never-ending discussions regarding implant selection. To document the efficiency of 
such an approach would further enhance the focus on surgical perfection and its 
importance for a successful outcome. 
In recent years, there have been several reports on mini-invasive plate and screw 
osteosynthesis, and results have been encouraging. However, as opposed to mini-
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invasive plating techniques for other fractures, for most surgeons this has not been 
established as a standard treatment for trochanteric and subtrochanteric fractures. 
Whether these techniques and corresponding implants could be favorable to all 
trochanteric fractures and patients, and even to surgeons not specifically dedicated to 
mini-invasive techniques, remains to be clarified. 
,QGLFDWLRQVFurthermore, rather thandiscussing whether a SHS or an IM nail is the 
best treatment for all trochanteric or subtrochanteric fractures, we should study and 
discuss to which subgroups of fractures or patients a SHS or an IM nail might be the 
best option. Our results suggest that a differentiated treatment algorithm probably best 
assures the individual patient a good outcome. Before we can draw definitive 
conclusions, and possibly tailor the treatment according to specific fracture and patient 
criteria, more research and detailed analyses of fracture and patient characteristics and 
outcome is required.  
,PSODQWGHVLJQDQGPHFKDQLFDOSURSHUWLHVThe basic mechanical principle for the 
modern sliding hip screw has remained practically unchanged since its introduction in 
the 60-ties and 70-ties. Similar, the basic principle for IM nails has been unchanged 
since the introduction of nailing in the treatment of trochanteric fractures in the late 
80-ties.   
However, modifications and improvements to previous generations of implants are 
continuously launched on the marked, and sometimes new concepts are presented. One 
such change is the principle of angular stability between screw and plate systems and 
between nails and their locking bolts. Another is the use of two integrated screws in 
the femoral head-neck fragment, until now most frequently used for IM nails (Intertan), 
but also available for recent plate and screw configurations.  
The osteoporotic structure of the bone in most hip fracture patients creates a poor 
environment for a stable fracture fixation. Therefore, attempts have been made to 
improve the bone-implant interface, and hydroxyapatite-coating of the implant surface 
and augmentation with cement around the femoral head-neck screw have been used to 
enhance screw fixation. The results so far indicate that there is still a way to go. 
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As the number of hip fractures will continue to rise, and mechanical failures will keep 
haunting patients and surgeons, the evolution of new products, and the search for the 
ideal implant will probably continue in foreseeable future. This implant should be 
dynamic, but stable, and the implant itself should aid the reduction and improve the 
healing capacity of the bone. And not the least, it should be cheap and easy to use. The 
question is will we ever get there?  
Finally, in my opinion, the surgical treatment and the implant selection should not 
merely be based on modern trends or beliefs that new implants or techniques are 
automatically better than existing methods. Any new implant or concept should be 
tested in well designed clinical trials before being launched on a large scale. 
11.4 Rehabilitation
The benefits (or limitations) of rehabilitation need to be clarified and scientifically 
documented for this group of elderly patients. In addition, and relevant to most health 
care systems with financial and other limitations, defining how to select the patients 
who will benefit the most from a structured rehabilitation program will be a major 
challenge.  
In general, as orthopaedic surgeons we are probably not doing enough for our patients 
after having repaired their fractures. Treating a hip fracture is not merely about 
repairing fractured bone, but even more importantly, it is a matter of restoring patients 
overall function and independency. Successful fracture healing is one prerequisite to 
achieve such a result, but fracture healing alone does not guarantee a pain free, well 
functioning, and independently living patient. Accordingly, more focus and research 
should be invested in how to optimize hip fracture care from a holistic approach, and 
not merely from a surgical point of view. 
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Appendix 1: 

+DUULVKLSVFRUH


6PHUWHU

Pain 1RQH  
 
6OLJKW 2FFDVLRQDODFKHRUDZDUHQHVVRISDLQRIORZJUDGHQRFRPSURPLVHRIDFWLYLWLHV 
0LOG 1RHIIHFWRQDYHUDJHDFWLYLWLHVUDUHO\PD\KDYHPRGHUDWHSDLQIROORZLQJXQXVXDODFWLYLWLHVPD\
WDNHDVSLULQH

0RGHUDWH 3DLQWROHUDEOHEXWSDWLHQWPDNHVFRQFHVVLRQVWRKLVSDLQVRPHOLPLWDWLRQVRIRUGLQDU\DFWLYLWLHVEXW
DEOHWRZRUNUHJXODU\PD\UHTXLUHSDLQPHGLFLQHVWURQJHUWKDQDVSLULQRFFDVLRQDOO\

0DUNHG 6HYHUHSDLQDWWLPHVEXWDPEXODWRU\VHULRXVOLPLWDWLRQVRIDFWLYLWLHVWDNHVSDLQPHGLFLQHVWURQJHU
WKDQDVSLULQHXVXDOO\RUIUHTXHQWO\

'LVDEOHG 6HYHUHSDLQHYHQLQEHGSDLQIRUFHVSDWLHQWWREHGFULSSOHGE\SDLQEHGULGGHQ 


$'/±IXQNVMRQHU


Walking stairs )RRWRYHUIRRWZLWKRXWXVHRIEDQLVWHUUHNNYHUN 
7UDSSHJDQJ )RRWRYHUIRRWXVLQJEDQLVWHU 
6WDLUVLQDQ\PDQQHU 
8QDEOHWRGRVWDLUV 

Transportation $EOHWRHQWHUSXEOLFWUDQVSRUWDWLRQ 

Sitting &RPIRUWDEOHLQDQ\FKDLUIRURQHKRXU 
 &RPIRUWDEOHLQDKLJKFKDLUIRURQHKDOIKRXU 
8QDEOHWRVLWFRPIRUWDEO\LQDQ\FKDLU 

Shoes and socks 3XWVRQVRFNVDQGWLHVVKRHVZLWKHDVH 
 3XWVRQVRFNVDQGWLHVVKRHVZLWKGLIILFXOW\ 
8QDEOHWRSXWRQVRFNVDQGWLHVKRHV 

*DQJIXQNVMRQ

Limp 1RQH 
+DOWLQJ 6OLJKW 
0RGHUDWH 
6HYHUH 

The support required to 
walk comfortably and 
smoothly
1RQH 
6LQJOHFDQHVWRNNIRUORQJZDONV 
6LQJOHFDQHPRVWRIWKHWLPH 
 2QHFUXWFKNU\NNH 
7ZRFDQHV 
7ZRFUXWFKHVVDPWUXOODWRUJnVWRO 
1RWDEOHWRZDONDWDOOnUVDN««««««««««««««««««« 

Distance walked 8QOLPLWHG 
*DQJGLVWDQVH 6L[EORFNVNP 
7ZRRUWKUHHEORFNVNP 
,QGRRUVRQO\ 
%HGDQGFKDLU 
6HWWULQJUXQGW
GHWULNWLJVWH
VYDUHW





'HIRUPLWHW

Abscence of deformity points DUHJLYHQLIWKHSDWLHQWGHPRQVWUDWHVQRQHRIWKHOLVWHGGHIRUPLWLHV 
 /HVVWKDQIL[HGIOH[LRQFRQWUDFWXUH        
 /HVVWKDQIL[HGDGGXFWLRQ        
 /HVVWKDQIL[HGLQWHUQDOURWDWLRQLQH[WHQVLRQ      
 /LPEOHQJKWGLVFUHSDQF\H[FHHGLQJFP      
 
)HLOVWLOOLQJHULenDYSDUDPHWUHQHVW¡UUHHQQGHWWHJLUSRHQJIRUGHIRUPLWHWVVFRUH    


7UHQGHOHQEXUJ6HWWULQJUXQGWULNWLJVYDU    

+¡\UHVLGH   1HJDWLY  3RVLWLY  .DQLNNHXWI¡UHV

9HQVWUHVLGH   1HJDWLY  3RVLWLY  .DQLNNHXWI¡UHV
 

7HVWHQHU´SRVLWLY´XQRUPDOSnVWDQGEHQHWVVLGHGHUVRPSDVLHQWHQLNNHNODUHUnKROGHEHNNHQHWL
YDWHUQnUGHWDQGUHEHQHWO¡IWHV


$QLVRPHOL6HWWULQJUXQGWULNWLJVYDU

+¡\UHVLGHHU««««FPOHQJUHHQQNRUWHUHHQQYHQVWUH


%HYHJHOVHVXWVODJ

+¡\UHKRIWH 9HQVWUHKRIWH
(NVWHQVMRQ  )OHNVMRQ  (NVWHQVMRQ  )OHNVMRQ 
8WURWDVMRQ  ,QQURWDVMRQ  8WURWDVMRQ  ,QQURWDVMRQ 
$EGXNVMRQ  $GGXNVMRQ  $EGXNVMRQ  $GGXNVMRQ 
(NVHPSHO
9HG(NVWHQVMRQ°RJIOHNVMRQ°DQJL°°9HGIOHNVMRQVNRQWUDNWXU°RJIOHNVMRQ°DQJL°°

5RWDVMRQPnOHVSnHNVWHQGHUWKRIWHPHGIRWHQVRPLQGLNDWRUIRUURWDVMRQ






6LJQDWXU«««««««««««««««««««««««««««««««


Appendix 2: 
 
(4'TXHVWLRQQDLUH

VISIT V / 12 måneders kontroll 

Utvalg fra EQ-5D 

 
PASIENTSPØRRESKJEMA   INTERTAN – STUDIEN 

 
Spørsmål om livskvalitet, smerte, funksjon og tilfredshet  



 
1.   Dato for utfylling av skjema:  _BB_BB__BB_BB__BB_BB_
 
 
2. Spørreskjemaet er besvart av: 

  0HJVHOY

eller ved hjelp av….(kryss av i ruten som gjelder) 
 
 
6OHNWQLQJHNWHIHOOHEDUQ
 *RGYHQQHOOHUDQQHQQ UVWnHQGH
 $QQHQSULYDWSHUVRQ
 +MHPPHV\NHSOHLHUKMHPPHKMHOS
 $QQHQSHUVRQDQJLKYHPBBBBBBBBBBBBBBBBBBBBBBBBBBB
 

 
 
…………………………………………………………. 
Signatur 
 
 
 
 
 

Vi har tidligere spurt deg hvordan du hadde det før du pådro deg bruddet i 
hoften, samt 1 og 3 måneder etter operasjonen. 
 
I de 5 neste spørsmålene ønsker vi å vite hvordan livssituasjonen din er NÅ:  
 
 
3. Hvordan opplever du gangevnen din?     
-HJKDULQJHQSUREOHPHUPHGnJnRPNULQJ
-HJKDUOLWWSUREOHPHUPHGnJnRPNULQJ
-HJHUVHQJHOLJJHQGH


4. Hvordan klarer du personlig stell? 
-HJKDULQJHQSUREOHPHUPHGSHUVRQOLJVWHOO
-HJKDUOLWWSUREOHPHUPHGnYDVNHPHJHOOHUNOHPHJ
-HJNODUHULNNHnYDVNHPHJHOOHUNOHPHJ


5. Hvordan klarer du dine vanlige gjøremål (f.eks. arbeid, studier,  
      husarbeid, familie- og fritidsaktiviteter)? 
-HJKDULQJHQSUREOHPHUPHGnXWI¡UHPLQHYDQOLJHJM¡UHPnO
-HJKDUOLWWSUREOHPHUPHGnXWI¡UHPLQHYDQOLJHJM¡UHPnO
-HJHUXWHDYVWDQGWLOnXWI¡UHPLQHYDQOLJHJM¡UHPnO
 
 
6. Smerter eller ubehag? 
-HJKDUYHUNHQVPHUWHHOOHUXEHKDJ
-HJKDUPRGHUDWVPHUWHHOOHUXEHKDJ
-HJKDUVWHUNVPHUWHHOOHUXEHKDJ


7. Angst eller depresjon? 
-HJHUYHUNHQHQJVWHOLJHOOHUGHSULPHUW
-HJHUQRHHQJVWHOLJHOOHUGHSULPHUW
-HJHUVY UWHQJVWHOLJHOOHUGHSULPHUW

        

   
 
 
 

8. Din helsetilstand i dag.  

)RU n KMHOSH IRON WLO n VL KYRU JRG HOOHU GnUOLJ HQ
KHOVHWLOVWDQG HU KDUYL ODJHW HQ VNDOD RPWUHQW VRPHW
WHUPRPHWHUKYRUGHQEHVWHWLOVWDQGHQGXNDQWHQNHGHJ
HU PHUNHW  RJ GHQ YHUVWH WLOVWDQGHQ GX NDQ WHQNH
GHJHUPHUNHW

9L YLO JMHUQH DW GX YLVHU Sn GHQQH VNDODHQ KYRU JRG
HOOHU GnUOLJ KHOVHWLOVWDQGHQ GLQ HU L GDJ HWWHU GLQ
RSSIDWQLQJ9 UYHQQOLJnJM¡UHGHWWHYHGn WUHNNHHQ
OLQMHIUDERNVHQQHGHQIRUWLOGHWSXQNWHWSnVNDODHQVRP
YLVHUKYRUJRGHOOHUGnUOLJGLQKHOVHWLOVWDQGHULGDJ

 
 
 
 
 
 
 














 
 
 
 
 
 
 
 
 
Din egen 
helsetilstand 
i dag
 
 
 
 
 
 
 
 
 

Verst tenkelige 
KHOVHWLOVWDQG

Best tenkelige 
KHOVHWLOVWDQG

 
 
9. Sett et kryss på den streken som du synes tilsvarer din gjennomsnittlige 
smerteopplevelse fra den opererte hoften den siste måneden: 
 
 
,QJHQ        0DNVLPDO
VPHUWH          VPHUWH 
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

OHWWPRGHUDWPLGGHOVVWHUNXXWKROGHOLJ

 
 
 
 
10. Sett et kryss på den streken som du synes tilsvarer hvor fornøyd du er 
med operasjonsresultatet: 
 
 
 
)RUQ¡\G          0LVIRUQ¡\G
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, 
 
            VY UWIRUQ¡\G IRUQ¡\G PLGGHOVIRUQ¡\G PLVIRUQ¡\GVY UWPLVIRUQ¡\G
 
 
 
Takk for at du tok deg tid til å svare på spørsmålene. Dine svar er svært 
nyttige for oss.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SMERTE 
TILFREDSHET 

Appendix 3: 
 
5DGLRJUDSKLFDVVHVVPHQWV

VISIT I og IILQQOHJJHOVHRJRSHUDVMRQ 
5DGLRORJLVNHUHJLVWUHULQJHUL,17(57$1678',(1
F.nr. (11 sifre) ………………………………………………………………………………… 
Navn: ……………………………………………………………………………………………       Reg.nr.: |__|__|__|  
 
Sykehus:    1 Diakonhjemmet     2 Levanger     3 AHUS     4 SIV     5 HUS 

Visit I (innleggelse)  5¡QWJHQGDWRGGPPnn««««««««

%UXGGNODVVLILNDVMRQ
$2NODVVLILNDVMRQHQIRUWURNDQW UHEUXGG
$ $Ƒ1  $Ƒ2  $Ƒ3
$  $Ƒ4  $Ƒ5  $Ƒ6
$  $Ƒ7  $Ƒ8  $Ƒ9

5XVVHOONODVVLILNDVMRQHQIRUVXEWURNDQW UHEUXGG
,DƑ1  ,EƑ2  ,,DƑ3 ,,EƑ4

6WDELOLWHWLKHQKROGWLO(YDQV.\OH6WDELOIUDNWXUƑ1 8VWDELOIUDNWXUƑ2

.RPPHQWDUHU«««««««««««««««««««««««««««««««

Visit II (postoperativt) 5¡QWJHQGDWRGGPPnn«««««««« 

)UDNWXUUHSRVLVMRQIURQWDOSODQ
 
´1HFNVKDIWDQJOH´ «««««JUDGHU
 
Avvik fra normalen: 
1HXWUDO9DOJXVƑ1 9DOJXVƑ2  9DOJXV!Ƒ3 
1HXWUDO9DUXVƑ4 9DUXVƑ5 9DUXV!Ƒ6
 
'LVORNDVMRQ (”displacement”): 
6NDIWYVSURNVLPDOW,QJHQƑ0 PPƑ1  !PPƑ2  !PPƑ3
7URNDQWHUPLQRU,QJHQƑ0 PPƑ1  !PPƑ2  !PPƑ3 
7URNDQWHUPDMRU,QJHQƑ0 PPƑ1  !PPƑ2  !PPƑ3 
 
)RUNRUWQLQJ,QJHQƑ0  PPƑ1  PPƑ2 !PPƑ3 

!PPƑ4  !PPƑ5  !PPƑ6 
 
)RUOHQJHOVH  1HLƑ0  -DƑ1 «««PP 

)UDNWXUUHSRVLVMRQVLGHSODQ
 
9LQNHOIHLOVWLOOLQJ: 
Antekruvasjon: 1HXWUDOƑ0  Ƒ1  ! Ƒ2 
Retrokurvasjon:     Ƒ3  !Ƒ4 
 
'LVORNDVMRQ (”displacement”): 
6NDIWYVWURFKDQWHU,QJHQƑ0 PPƑ1  !PPƑ2  !PPƑ3 
7URNDQWHUPLQRU,QJHQƑ0 PPƑ1  !PPƑ2  !PPƑ3 
7URNDQWHUPDMRU,QJHQƑ0 PPƑ1  !PPƑ2  !PPƑ3 
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VISIT V, 0c1('(56.21752//
5DGLRORJLVNHUHJLVWUHULQJHUL,17(57$1678',(1
             
F.nr. (11 sifre) ………………………………………………………………………………… 
…. 
Navn: ……………………………………………………………………………………………      Reg.nr.: 
|__|__|__|  
 
Sykehus:    1 Diakonhjemmet     2 Levanger     3 AHUS     4 SIV     5 HUS  

5¡QWJHQELOGHUWDWWGGPPnn_BB_BB__BB_BB__BB_BB_ 

5HRSHUHUWVLGHQPnQHGHUVNWU 1HL0 -D1……………………………

7LOKHOLQJ    1HL0  -D1   8VLNNHU2
       
)UDNWXUVWLOOLQJIURQWDOSODQ
 
´1HFNVKDIWDQJOH´ «««««JUDGHU  (QGULQJIUDVLVW««««JUDGHU
 
Avvik fra normalen: 
1HXWUDO9DOJXVƑ1 9DOJXVƑ2  9DOJXV!Ƒ3 
1HXWUDO9DUXVƑ4 9DUXVƑ5 9DUXV!Ƒ6
 

)RUNRUWQLQJLEUXGGHW
,QJHQƑ0  PPƑ1  PPƑ2 !PPƑ3   
!PPƑ4  !PPƑ5  !PPƑ6 
 
Medialisering av skaftet: Ƒ««««PPHQGULQJIUDPQGNWU 
 
$QGUH
NRPPHQWDUHU«««««««««««««««««««««««««««««
 
,PSODQWDWHQGULQJHU
 
Uendret siden sist: 0  
Endring siden sist: 1 ´&XWRXW´DYVNUXHQ*MHQQRPFDSXW 1
     %HYHJHOVHDYVNUXHQLFDSXW 2   «««PP
/HGGSHQHWUDVMRQPLJUDVMRQ   3 
    7HOHVNRSHULQJDYVNUXHQLFROOXPFDSXW 4
 «««PP
/¡VQLQJDYLPSODQWDWIUDIHPXU  5 
    6NUXHEUHNNDVMHJOLGHVNUXH   6 
    6NUXHEUHNNDVMHVSHUUHVNUXHQDJOH  7 

$QGUHHQGULQJHU«««««««««««««««««««««««««««««

«««««««««««««««««««««««««««««
'DWRVLJQDWXU
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1DVMRQDOW5HJLVWHUIRU/HGGSURWHVHU
+HOVH%HUJHQ+)2UWRSHGLVNNOLQLNN
+DXNHODQG8QLYHUVLWHWVV\NHKXV
0¡OOHQGDOVEDNNHQ
%(5*(1
7OI
+2)7(%58''
PRIMÆRE OPERASJONER PÅ BRUDD I PROKSIMALE FEMURENDE og ALLE REOPERASJONER, inkludert
lukket reponering av hemiproteser.   Ved primæroperasjon med totalprotese og ved reoperasjon til totalprotese brukes
kun hofteproteseskjema.  Alle produktklistrelapper settes i merket felt på baksiden av skjemaet.
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 NASJONALT HOFTEBRUDDREGISTER 
 Nasjonalt Register for Leddproteser 
 Helse Bergen HF, Ortopedisk klinikk 
 Haukeland Universitetssykehus 
 Møllendalsbakken 11 
 5021 BERGEN 
 Tlf: 55976452  
 
HOFTEBRUDD 
PRIMÆRE OPERASJONER PÅ BRUDD I PROKSIMALE FEMURENDE og ALLE REOPERASJONER, inkludert 
lukket reponering av hemiproteser.   Ved primæroperasjon med totalprotese og ved reoperasjon til totalprotese brukes 
kun hofteproteseskjema.  Alle produktklistrelapper settes i merket felt på baksiden av skjemaet.  
 
F.nr. (11 sifre)..................................................................... 
Navn:.................................................................................. 
 
(Skriv tydelig ev. pasient klistrelapp – spesifiser sykehus.) 
Sykehus:............................................................................ 
AKTUELLE OPERASJON 
  1 Primæroperasjon  2 Reoperasjon 
 
SIDE (ett kryss)  (Bilateral opr.= 2 skjema) 
  1 Høyre 2 Venstre 
  
OPR TIDSPUNKT   (dd.mm.åå)  |__|__| |__|__| |__|__|  kl |__|__| 
 
BRUDD TIDSPUNKT    (dd.mm.åå) |__|__| |__|__| |__|__|  kl |__|__| 
      
          Dersom det er usikkerhet om brudd tidspunkt, fyll ut neste punkt. 
 
 TID FRA BRUDD TIL OPERASJON I TIMER  
     1 0-6     2 >6-12     3 >12-24     4 >24-48    5 >48 
 
DEMENS  
  0 Nei  1 Ja (Se test på baksiden) 2 Usikker 
 
ASA-KLASSE  (se bakside av skjema for definisjon) 
 1 Frisk  
 2 Asymptomatisk tilstand som gir økt risiko 
 3 Symptomatisk sykdom 
 4 Livstruende sykdom 
 5 Moribund 
 
 
TYPE PRIMÆRBRUDD (ÅRSAK TIL PRIMÆROPERASJON) (Kun ett kryss) 
 Se baksiden for klassifikasjon 
 1 Lårhalsbrudd udislokert  (Garden 1 og 2) 
 2 Lårhalsbrudd dislokert   (Garden 3 og 4) 
 3 Lateralt lårhalsbrudd  
 4 Pertrokantært tofragment   (AO klassifikasjon A1)  
 5 Pertrokantært flerfragment  (AO klassifikasjon A2) 
 9 Intertrokantært (AO klassifikasjon A3) 
 6 Subtrokantært 
 7 Annet ………………………………………………………………………… 
 
TYPE PRIMÆROPERASJON (Kun ett kryss)  
    (Fylles ut bare ved primæroperasjon - eget skjema for totalproteser)  
    (Spesifiser nøyaktig produkt eller fest evt produktklistrelapp på baksiden) 
 1 To skruer eller pinner  
 2 Tre skruer eller pinner 
 3 Bipolar hemiprotese 
 4 Unipolar hemiprotese 
 5 Glideskrue og plate 
 6 Glideskrue og plate med trochantær støtteplate 
 7 Vinkelplate 
 8 Kort margnagle uten distal sperre 
 9 Kort margnagle med distal sperre 
 10 Lang margnagle uten distal sperre 
 11 Lang margnagle med distal sperre 
 12 Annet, spesifiser.…………………………………….….……….………... 
 
 Navn / størrelse ev. katalognummer……………………………………… 
 
ÅRSAK TIL REOPERASJON (Flere enn ett kryss kan brukes) 
 1 Osteosyntesesvikt/havari 
2 Ikke tilhelet brudd (non-union/pseudartrose) 
3 Caputnekrose (segmentalt kollaps) 
4 Lokal smerte pga prominerende osteosyntesemateriale 
5 Brudd tilhelet med feilstilling 
6 Sårinfeksjon – overfladisk 
7 Sårinfeksjon – dyp 
8 Hematom 
9 Luksasjon av hemiprotese 
10 Osteosyntesematerialet skåret gjennom caput 
11 Nytt brudd rundt implantat 
12 Løsning av hemiprotese  
13 Annet, spesifiser.…………………………………..………………………. 
TYPE REOPERASJON (Flere enn ett kryss kan brukes) 
     (Spesifiser nøyaktig produkt eller fest evt produktklistrelapp på baksiden) 
   1 Fjerning av implantat (Brukes når dette er eneste prosedyre) 
   2 Girdlestone  
     (= fjerning av osteosyntesemateriale/hemiprot. og caputresten) 
   3 Bipolar hemiprotese 
   4 Unipolar hemiprotese 
   5 Re-osteosyntese  
   6 Drenasje av hematom eller infeksjon 
   7 Lukket reposisjon av luksert hemiprotese 
   8 Åpen reposisjon av luksert hemiprotese 
   9 Annet, spesifiser……………………….……………………………………… 
  
           Navn / størrelse ev. katalognummer…………………………………….…. 
 
FIKSASJON AV HEMIPROTESE 
      (For totalprotese sendes eget skjema til hofteproteseregisteret)  
           1 Usementert 
 1  med HA 2 uten HA 
           2 Sement med antibiotika  Navn…………………………………………….…. 
 
           3 Sement uten antibiotika  Navn……………………………………………….. 
 
PATOLOGISK BRUDD (Annen patologi enn osteoporose) 
           0  Nei  
           1  Ja, type.………………………………………………………………………... 
 
TILGANG TIL HOFTELEDDET VED HEMIPROTESE (Kun ett kryss) 
           1 Anterolateral 
           2 Lateral  
           3 Posterolateral 
           4 Annet, spesifiser………………………………..…..………………………..... 
 
ANESTESITYPE 
           1 Narkose  2 Spinal  3 Annet, spesifiser…………………………………... 
 
PEROPERATIVE KOMPLIKASJONER  
           0  Nei    
           1  Ja, hvilke(n)...................................................................................……….. 
     
OPERASJONSTID (hud til hud).......................minutter. 
 
SYSTEMISK ANTIBIOTIKAPROFYLAKSE 
          0 Nei 1 Ja, Hvilken (A)................................................................................ 
    
           Dose (A).............….Totalt antall doser...……….....Varighet .……..........timer  
          
           Ev. i kombinasjon med (B)......................................................................... 
           
           Dose (B).........….....Totalt antall doser.....……......Varighet ....…….......timer 
 
TROMBOSEPROFYLAKSE  
          0 Nei  1 Ja, hvilken type………………………………………………………… 
     
           Dosering opr.dag………………………..Første dose gitt preopr 0 Nei 1 Ja 
 
           Senere dosering…………………………………….Antatt varighet.….……døgn 
 
           Ev. i kombinasjon med ………………………...……………………..……….….. 
         
           Dosering..……………………………………..…….Antatt varighet..…….…døgn 
 
 Strømpe  0 Nei 1 Legg 2 Legg + Lår          Antatt varighet .….……døgn 
 
          Mekanisk pumpe 0 Nei 1 Fot  2 Legg         Antatt varighet.………...døgn 
 
 
Lege....................................................................................................  
Legen som har fylt ut skjemaet (navnet registreres ikke i databasen). 
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1RUZHJLDQ$UWKURSODVW\5HJLVWHU
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PRIMARY OPERATIONS ON PROXIMAL FEMORAL FRACTURES and ALL REVISIONS, included closed
reduction of hemiprosthesis.   When primary operation with total hip arthroplasty and revision with total hip arthroplasty
use form to the arthroplasty register only.  All stickers are to be put in marked area on back of form.
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